FDA inspection found problems at factory making J&J vaccine
Agency inspectors said a batch of the bulk drug substance for J&J's single-shot vaccine was contaminated with material used to make COVID-19 vaccines for another Emergent client, AstraZeneca. That batch, reportedly enough to make about 15 million J&J vaccine doses, had to be thrown out.
Share:
More Stories
Hometown Heroes in New York City
141ds ago
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
437ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
448ds ago1:54
Hochul: Updated COVID vaccine to be available in NY in the coming days
455ds ago2:22
New and rare COVID variant detected in NYC wastewater; Gov. Hochul urges caution
469ds ago2:39
City health officials: COVID-19 cases on the rise as new variant emerges
470ds agoHometown Heroes in New York City
141ds agoNobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
437ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
448ds ago1:54
Hochul: Updated COVID vaccine to be available in NY in the coming days
455ds ago2:22
New and rare COVID variant detected in NYC wastewater; Gov. Hochul urges caution
469ds ago2:39
City health officials: COVID-19 cases on the rise as new variant emerges
470ds ago
The Baltimore factory contracted to make Johnson & Johnson’s COVID-19 vaccine was dirty, didn’t follow proper manufacturing procedures and had poorly trained staff, resulting in contamination of material that was going to be put in the shots, U.S. regulators said Wednesday.
The Food and Drug Administration released a statement and a 13-page report detailing findings from its recent inspection of the now-idle Emergent Biosciences factory.
Agency inspectors said a batch of the bulk drug substance for J&J's single-shot vaccine was contaminated with material used to make COVID-19 vaccines for another Emergent client, AstraZeneca. That batch, reportedly enough to make about 15 million J&J vaccine doses, had to be thrown out.
SEARCH FOR A CURE: Statistics and State Resources
Other problems cited in the inspection report were peeling paint, black and brown residue on floors and walls in the factory, inadequate cleaning and employees not following procedures to prevent contamination.
Both Emergent and Johnson & Johnson said Wednesday that they are working to fix the problems as quickly as possible. Nothing made at the factory for J&J has been distributed yet.
At the moment, use of the J&J vaccine is on hold in the U.S. as government health officials investigate its connection to very rare blood clots. The nearly 8 million doses of J&J vaccine that had been used in the U.S. came from European sources.
The Baltimore factory halted production late last week at the request of the FDA. The agency hasn’t given emergency approval to the factory, which is needed before any vaccine material made at the factory can be distributed.
All the bulk vaccine substance Emergent has made is being stored and will undergo additional testing by the FDA, the agency said.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
(Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.)
More from News 12
Your Road Trip Close to Home adventure guide for Dec. 12
1:58
Tree falls, crushes multiple parked cars in Soundview
1:31
Tips for businesses to thrive with rising rent
1:04
The East End: Gingerbread University in Riverhead
1:40
Cold, dry and windy with feel-like temps in the 20s for the Bronx
1:45
